The objective of the Genetically Engineered Mouse (GEM) Resource is to aid Cancer Center investigatorswith the design and execution of experiments to utilize animal models for the investigation of the progressionof cancer and for the preclinical evaluation of therapies for the treatment of cancer. Although the use ofanimal models provides an invaluable source of reagents for preclinical testing and the investigation ofregulatory mechanisms in vivo in a physiologically regulated system, the use of animals is costly with respectto equipment, animal resources, and technical expertise. The GEM Core will serve as a resource forcarrying out and training in the use of all animal manipulations needed in the Cancer Center. The GEM Corewill minimize the cost of utilizing animal models in the Cancer Center by consolidating the equipment,expertise, and animal resources. This will ensure an efficient use of animal research at minimal cost.The GEM Core will serve Cancer Center investigators by aiding in the following tasks.1. The GEM Core will generate transgenic mice by the micro injection of DMA into one-celled mouseembryos.2. The GEM Core will generate mutant mice by the manipulation of mouse Embryonic Stem Cells.3. The Core will preserve lines of mice by cryopreservation.4 The Core will aid investigators with the importation and exporting of lines of mice.The accomplishments of these tasks will allow the GEM Core to serve as a repository for all geneticallyengineered mouse models and techniques for Cancer Center investigators and will ensure efficient use ofanimal resources by Cancer Center investigators. The Shared Resource Leader is Dr. Francesco DeMayo,who has an extensive track record in these areas

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA125123-01
Application #
7514629
Study Section
Subcommittee G - Education (NCI)
Project Start
2007-07-01
Project End
2010-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
1
Fiscal Year
2007
Total Cost
$83,853
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Badr, Hoda; Herbert, Krista; Bonnen, Mark D et al. (2018) Dyadic Coping in Patients Undergoing Radiotherapy for Head and Neck Cancer and Their Spouses. Front Psychol 9:1780
Morita, Daisuke; Nishio, Nobuhiro; Saito, Shoji et al. (2018) Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in piggyBac Transposon-Engineered T Cells. Mol Ther Methods Clin Dev 8:131-140
Bajgain, Pradip; Tawinwung, Supannikar; D'Elia, Lindsey et al. (2018) CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 6:34
Ballester, Leomar Y; Lu, Guangrong; Zorofchian, Soheil et al. (2018) Analysis of cerebrospinal fluid metabolites in patients with primary or metastatic central nervous system tumors. Acta Neuropathol Commun 6:85
Bollard, Catherine M; Tripic, Tamara; Cruz, Conrad Russell et al. (2018) Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. J Clin Oncol 36:1128-1139
Gates, Leah A; Gu, Guowei; Chen, Yue et al. (2018) Proteomic profiling identifies key coactivators utilized by mutant ER? proteins as potential new therapeutic targets. Oncogene 37:4581-4598
Shi, Xiangguo; Kitano, Ayumi; Jiang, Yajian et al. (2018) Clonal expansion and myeloid leukemia progression modeled by multiplex gene editing of murine hematopoietic progenitor cells. Exp Hematol 64:33-44.e5
Dasgupta, Subhamoy; Rajapakshe, Kimal; Zhu, Bokai et al. (2018) Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature 556:249-254
Qin, Liying; Sankaran, Banumathi; Aminzai, Sahar et al. (2018) Structural basis for selective inhibition of human PKG I? by the balanol-like compound N46. J Biol Chem 293:10985-10992
Chapple, Richard H; Tseng, Yu-Jung; Hu, Tianyuan et al. (2018) Lineage tracing of murine adult hematopoietic stem cells reveals active contribution to steady-state hematopoiesis. Blood Adv 2:1220-1228

Showing the most recent 10 out of 991 publications